Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study

Table 5 Exploratory analysis of the relationships between overall work impairment outcomes and type of drug received

	TCZ-SC group				csDMARDs-alone group
Work impairment measures	n	Standardized regression coefficient	95% CI	P value	n	Standardized regression coefficient	95% CI	P value
Presenteeism (%)	143	−0.5751	−0.7214, −0.4289	< 0.0001	147	−0.6999	−0.8240, −0.5758	< 0.0001
Overall work impairment (%)	143	−0.5950	−0.7393, −0.4507	< 0.0001	147	−0.6845	−0.8094, −0.5595	< 0.0001
Activity impairment (%)	143	−0.4754	−0.6287, −0.3221	< 0.0001	147	−0.5008	−0.6562, −0.3453	< 0.0001
HAQ-DI	143	−0.4107	−0.5707, −0.2508	< 0.0001	147	−0.1920	−0.3696, −0.0145	0.0343
EQ-5D	143	0.2840	0.1164, 0.4516	0.0011	147	0.2872	0.1126, 0.4618	0.0014
DAS28-ESR	143	−0.2961	−0.4581, −0.1342	0.0004	147	−0.2434	−0.4140, −0.0729	0.0055
CDAI	143	−0.1629	−0.3320, 0.0061	0.0587	147	−0.1608	−0.3287, 0.0070	0.0602
SDAI	143	−0.2030	−0.3709, −0.0351	0.0182	147	−0.1639	−0.3321, 0.0043	0.0560
WFun	143	−0.3748	−0.5403, −0.2092	< 0.0001	147	−0.1875	−0.3544, −0.0206	0.0280
K6	143	−0.1408	−0.3142, 0.0327	0.1108	147	−0.2002	−0.3704, − 0.0300	0.0215

Adjusted for sex, age, disease duration, job type, use of methotrexate, Steinbrocker stage, and Steinbrocker class
CDAI clinical disease activity index, CI confidence interval, csDMARD conventional synthetic disease-modifying antirheumatic drug, DAS28-ESR disease activity score in 28 joints using the erythrocyte sedimentation rate, EQ-5D EuroQol 5 dimension, HAQ-DI health assessment questionnaire disability index, K6 6-item Kessler psychological distress scale, SDAI simplified disease activity index, TCZ-SC tocilizumab by subcutaneous injection, WFun work functioning impairment scale

ISSN: 1478-6362